(firstQuint)Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU.

 165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU.

 This study is open only to adults who have been exposed to BMN165 in a previous study.

 Study BMN 165-302 is a four-part, Phase 3 study.

 - PART 1: Open-label period - PART 2: A Randomized, double-blind, placebo-controlled period of 8 weeks - PART 3: PK (plasma BMN 165) and PD (plasma Phe) assessment.

 - Part 4: A long-term, open-label extension study.

.

 Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU@highlight

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.

